doi:10.1007/s10096-020-04139-5engFuentes, A.Serrano-Conde, E.Roldán, C.Benito-Ruesca, R.Mejías, G.Sampedro, A.March-Roselló, G.Fernández-Natal, I.Esperalba, J.Rodríguez, M.J.Martínez de Aguirre, P.Salas, C.Roc, M.L.Soria, L.M.Parra-Grande, M.Montero, M.D.Fernández-Roblas, R.Franco-Álvarez de Luna, F.Lozano, C.García, F.Antibody response in patients admitted to the hospital with suspected SARS-CoV-2 infection: results from a multicenter study across SpainART-2021-123386Aim: To evaluate the serological response against SARS-CoV-2 in a multicenter study representative of the Spanish COVID pandemic. Methods: IgG and IgM + IgA responses were measured on 1466 samples from 1236 Spanish COVID-19 patients admitted to the hospital, two commercial ELISA kits (Vircell SL, Spain) based on the detection of antibodies against the viral spike protein and nucleoprotein, were used. Results: Approximately half of the patients presented antibodies (56.8% were IgM + IgA positive and 43.0% were IgG positive) as soon as 2 days after the first positive PCR result. Serological test positivity increased with time from the PCR test, and 10 days after the first PCR result, 91.5% and 88.0% of the patients presented IgM + IgA and IgG antibodies, respectively. Conclusion: The high values of sensitivity attained in the present study from a relatively early period of time after hospitalization support the use of the evaluated serological assays as supplementary diagnostic tests for the clinical management of COVID-19.2021http://zaguan.unizar.es/record/9981610.1007/s10096-020-04139-5http://zaguan.unizar.es/record/99816oai:zaguan.unizar.es:99816EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES 40 (2021), 1343–1349byhttp://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccess